GLP-1 Weight Loss: Price Cuts & Deals Expand Reach Beyond Urban Elites

• GLP-1 weight loss drugs like Wegovy and Mounjaro have achieved over Rs 1,000-crore sales in India.
• Sales are concentrated in affluent urban areas, with Mumbai, Delhi, and Bengaluru accounting for one-third of the market.
• High costs, limited accessibility, and low awareness restrict wider adoption, especially in non-urban regions despite high obesity prevalence.
• Companies are implementing price cuts and forming distribution partnerships with Indian drugmakers (e.g., Lilly-Cipla, Novo Nordisk-Emcure) to expand reach.
• Future generic versions, expected post-March 2026, could significantly lower prices and boost penetration in Tier-2 and Tier-3 cities.

Why It Matters: Efforts to cut prices and expand distribution could democratize GLP-1 weight loss drugs.